RE: TFChem/SironaHere is affirmation that TFCHEM and Sirona are in the process of developing a superior diabetes and obesity drug by combining the two technologies. They've been working together for a while now and I'm suggesting and hoping if the outlook did not look great for this business and technology combination, it would have not happened.
I'm looking forward to more news about the what they have been finding.
"
Dr. Verrico said management of sugar metabolism is a primary medicalchallenge associated with treating diabetes and obesity and that is whySGLT inhibitors show such promise in this regard. “At present SGLT2inhibitors have demonstrated their ability to limit the re-uptake ofglucose back into the blood stream from urine. However, they have beennotoriously lacking in ability to resist being rapidly metabolized bythe body, thus rendering them largely ineffective. (I think Glycomim changes that characteristic of present SGLT2 inhibitors making this one much more effective by staying longer in the body)
“What we have now done is show that our molecules, with their uniqueGlycoMim® technology, can inhibit the glucose transporter SGLT2. Thenext challenge, and an exciting one, is to show that our molecules areselective, safe and have the potential to have an increased efficacycompared to the current molecules undergoing clinical development.” (I take this to mean that that the drug is in the final proof stages)